The pharmaceutical industry lost the third ruling in litigation challenging the Inflation Reduction Act’s Medicare drug price negotiation program when the Delaware district court ruled against AstraZeneca LP’s claims the law is unconstitutional and violates its Fifth Amendment right to due process.
Second Judge Rejects Constitutional Challenges To Medicare Price Negotiation Program
Delaware district judge rules against AstraZeneca’s claim the IRA violates its due process rights, echoing findings made by Ohio district judge in Chamber of Commerce’s suit. Only other IRA ruling to date dismissed PhRMA’s complaint on procedural grounds without addressing the merits.
